<DOC>
	<DOCNO>NCT01223664</DOCNO>
	<brief_summary>The objective study evaluate therapeutic efficacy allogenic bone marrow stem cell ( BMSCs ) transplantation patient liver cirrhosis . The evaluation efficacy include level serum alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , total bilirubin ( TB ) , prothrombin time ( PT ) , albumin ( ALB ) , prealbumin ( PA ) , precollagenⅢ ( PCⅢ ) , collagenⅣ ( Ⅳ-C ) , laminin ( LN ) , hyaluronidase ( HN ) , liver histological improvement 1 week 1 year transplantation . Child-Pugh score clinical symptom also observe simultaneously .</brief_summary>
	<brief_title>Allogenic Bone Marrow Stem Cells Transplantation Patients With Liver Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Aged 16~65 year . Serum HBsAg positive six month . Ultrasonographic evidence cirrhosis History moderate severe hepatic encephalopathy variceal bleed last two month enrolment . Prothrombin time 30 . Cirrhosis cause reason except HBV infection . Severe problem vital organ ( e.g.the heart , renal lung ) . Liver tumor ultrasonography , CT MRI examination . Pregnant lactating woman . Imaging evidence vascular thromboses .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>ABMSC</keyword>
	<keyword>Allogenic bone marrow mesenchymal stem cell</keyword>
	<keyword>Liver cirrhosis</keyword>
	<keyword>Transplantation</keyword>
</DOC>